Should Activist Pushback on Leverage and M&A Strategy Require Action From H.B. Fuller (FUL) Investors?

• On May 26, 2026, Ancora Holdings Group publicly urged H.B. Fuller to abandon talks to acquire Advanced Medical Solutions Group and instead launch a full strategic review, including potential sale options, citing concerns about higher leverage, integration risk, and deviations from prior deleveraging commitments.
• The clash highlights a widening gap between management’s acquisition-led growth ambitions and an activist investor’s push for tighter balance sheet discipline and exploration of alternative paths to unlock value.
• Next, we’ll examine how Ancora’s opposition to increased leverage through acquisitions could reshape H.B. Fuller’s existing investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 47 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

H.B. Fuller Investment Narrative Recap

To own H.B. Fuller, you need to be comfortable with a specialty adhesives story that leans on disciplined M&A and steady cash generation while managing elevated leverage. Ancora’s call to halt the AMS deal and pursue a strategic review directly targets the most immediate catalyst, the potential acquisition, and amplifies the key short term risk around already high net debt and balance sheet flexibility.

The recent Q1 2026 update, where H.B. Fuller raised its full year net revenue guidance and reiterated modest near term growth expectations, is central to judging this tension. That guidance, combined with an increased quarterly dividend to US$0.2450 per share in April 2026, frames how much room management has to pursue deals without further straining a capital structure that activists are already questioning.

Yet behind the acquisition headlines, the elevated net debt to EBITDA level remains a risk investors should be aware of as...

Read the full narrative on H.B. Fuller (it's free!)

H.B. Fuller's narrative projects $3.9 billion revenue and $243.6 million earnings by 2029. This requires 4.5% yearly revenue growth and a $83.8 million earnings increase from $159.8 million today.

Uncover how H.B. Fuller's forecasts yield a $70.43 fair value, a 14% upside to its current price.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community sit between US$59.02 and US$70.43 per share, showing how far apart individual views can be. When you weigh those against concerns about higher leverage and limited financial flexibility, it underlines why many market participants scrutinize balance sheet risk before forming an opinion on H.B. Fuller’s potential performance.

Explore 2 other fair value estimates on H.B. Fuller - why the stock might be worth as much as 14% more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your H.B. Fuller research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free H.B. Fuller research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate H.B. Fuller's overall financial health at a glance.

Ready For A Different Approach?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Find 47 companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com